Genetically Modified Mouse Models Professors and Supervisors | ApplySharif

Find Academic Supervisors

Find and connect with academic supervisors, professors, and scholars for your research journey.

Showing 466-480 of 527 supervisors

Profile data may be stale. It is sourced from public faculty pages.

Abdenour SoufiView profile

Senior Lecturer

University of EdinburghUnited Kingdom

Abdenour Soufi serves as a Senior Lecturer in the School of Biological Sciences at the University of Edinburgh, leading research within the Centre for Regenerative Medicine and Institute for Regeneration and Repair. His laboratory investigates chromatin structure dynamics and cellular identity mechanisms with focus on developing safe reprogramming technologies for regenerative medicine. Dr. Soufi's research centers on chromatin structure and cellular identity , specifically examining how reprogramming factors (Oct4, Sox2, Klf4, c-Myc) convert fibroblasts to induced pluripotent stem cells. His group discovered that OSKM factors interact differently with fibroblast genomes compared to embryonic stem cells and face barriers accessing critical genomic regions. This foundational work drives their current efforts to engineer synthetic reprogramming factors that avoid tumorigenic risks associated with conventional methods. Analysis of his 12 publications (2014-2024) reveals consistent focus on nucleosome dynamics , transcription factor binding mechanisms , and cellular reprogramming barriers . His 2024 Nature paper demonstrates how nucleosome topology guides enhancer binding, while earlier work established how pioneer factors target partial DNA motifs on nucleosomes. Research spans fundamental chromatin biochemistry to translational applications in cancer and regenerative medicine. Scientific Awards and Recognition: MRC Career Development Award University of Edinburgh Chancellor's Fellowship Darwin Trust of Edinburgh Fellowship Diabetes Research & Wellness Foundation Grant Dr. Soufi actively supervises six PhD students including Katharine Furlong and Michael O'Dwyer, and collaborates extensively with Edinburgh colleagues (Chambers, Kaji, Lowell) and international partners (Buganim, Jauch, Skoultchi). His research receives funding from CRUK, EPSRC, MRC, and BBSRC. The Soufi group maintains strong ties with the Edinburgh Mammalian Synthetic Biology Research Centre and focuses on developing clinically viable reprogramming technologies through interdisciplinary approaches combining biochemistry, genomics, and synthetic biology.

Official University Profile

Shannon DavisView profile

Associate Professor

University of South CarolinaUnited States

Shannon Davis is an Associate Professor in the Department of Biological Sciences at the University of South Carolina's McCausland College of Arts and Sciences. Her research focuses on stem cells and developmental biology, with a particular emphasis on pituitary gland organogenesis and genetic variability in Peromyscus rodents. Research Interests: Pituitary gland development, WNT signaling, genetic modifiers, and molecular mechanisms of hormone production. Key Collaborators: Samuel A. Camper (University of Michigan), Marla Brinkmeier, Lisa Y. Cheung, and others in pituitary and stem cell research. Her work leverages knockout mice from the International Knockout Mouse Project to study gene functions during development, linking traits like the Dominant Spot in Peromyscus to the Sox10 gene. She has authored numerous publications in journals such as Human Molecular Genetics , Cell Metabolism , and Nature Communications , often employing bioinformatics and genomic approaches. Notable trends in her recent articles include: Regulation of pituitary stem cell differentiation via WNT signaling and nucleoredoxin (2025) Investigation of obesity-induced disruptions in pituitary-hepatic communication (2024) Use of knockout models to identify human hypopituitarism cases (2024) Exploration of epigenetic mechanisms in neuronal circuitry (2022) While no specific scientific awards are detailed, her contributions span developmental biology, genetics, and computational methods in single-cell transcriptomics. Her lab integrates Peromyscus genetics with human health implications, particularly in hormone-related disorders.

Official University Profile

Joshua D WytheView profile

Associate Professor

University of VirginiaUnited States

Joshua D. Wythe is an Associate Professor in the Department of Cell and Developmental Biology at the University of Virginia School of Medicine. His research focuses on the molecular and genetic mechanisms underlying cardiovascular development and cerebrovascular pathologies, with a particular emphasis on endothelial cell differentiation and brain vascular diseases such as arteriovenous malformations and glioblastoma. He leads the Wythe Lab, which utilizes zebrafish and mouse models combined with bioinformatics, functional genomics, and 3D imaging to investigate blood vessel formation and dysfunction. BA in History, Miami University BS in Botany, Miami University PhD in Oncological Sciences / Cardiovascular Development, University of Utah School of Medicine Postdoctoral Fellowship in Cardiovascular Development and Disease, University of California, San Francisco Dr. Wythe's research interests span cardiovascular biology, developmental biology, transcriptional regulation, and translational science. His lab investigates how transcriptional networks govern endothelial plasticity, the role of RAS/MEK/ERK signaling in brain arteriovenous malformations, and novel therapeutic targets in glioblastoma. The work integrates molecular genetics, imaging, and bioinformatics to understand both normal vascular development and pathological conditions. The recent publications reflect a strong trend in vascular development, disease modeling, and technological innovation. Key themes include transcriptional control of endothelial identity, signaling pathways in vascular malformations, and advanced imaging techniques for 3D tissue visualization. The research spans from basic developmental mechanisms to translational applications in brain cancers and cerebrovascular disorders. Dr. Wythe actively mentors graduate students, postdoctoral fellows, and undergraduates, fostering a collaborative and interdisciplinary research environment. His lab is currently recruiting researchers with expertise in developmental biology, genomics, bioinformatics, and imaging. Funding supports multiple projects aimed at uncovering transcriptional regulators essential for cardiovascular function and disease. The Wythe Lab is equipped to conduct cutting-edge research using genetically modified animal models, single-cell analyses, and advanced microscopy. The team develops and shares resources such as FishNET for zebrafish colony management and EZ Clear for tissue clearing, contributing to the broader scientific community.

Official University Profile

John ScottView profile

Research Fellow

Monash UniversityAustralia

John Scott is a Senior Research Fellow and Group Leader in the Drug Discovery Biology theme at the Monash Institute of Pharmaceutical Sciences (MIPS), Monash University. He holds an Honorary Senior Research Fellow position at the Florey Institute of Neuroscience and Mental Health and a Senior Research Associate role at St Vincent’s Institute of Medical Research (SVI), reflecting his strong interdisciplinary affiliations in neuroscience, metabolism, and drug discovery. Bachelor of Science (Hons), University of Glasgow PhD in Biochemistry, University of Dundee (Wellcome Trust Prize Scholar) Dr Scott’s research focuses on kinase signaling pathways, particularly CaMKK2, which regulates brain function and whole-body energy metabolism. His work has established links between CaMKK2 dysfunction and psychiatric disorders such as bipolar disorder and schizophrenia. He employs biochemical, cellular, and genetically modified mouse models to investigate these pathways. His recent research output centers on metabolite-sensing mechanisms, psychiatric disease modeling, and therapeutic target validation. Articles highlight work on AMPK regulation, CaMKK2’s role in mood disorders, and metabolic interventions in obesity and liver disease. Dr Scott leads major research projects funded by the NHMRC and ARC, including Validating CaMKK2 as a Rational Treatment Target for Bipolar Disorder and Uncovering New Mechanisms of Metabolite-Sensing and Signaling . These projects underscore his leadership in translational neuroscience and metabolism research. He supervises PhD students and collaborates internationally with academic and industrial partners to develop novel therapeutics targeting CaMKK2. His team utilizes advanced techniques such as protein crystallography, mass spectrometry, and in vivo modeling.

Official University Profile

Brian HendrichView profile

Research Fellow

University of CambridgeUnited Kingdom

Dr Brian Hendrich is a Principal Research Fellow at the Cambridge Stem Cell Institute , affiliated with the Department of Biochemistry at the University of Cambridge. His research focuses on the transcriptional control of stem cell fate, particularly the role of chromatin-modifying proteins like the NuRD complex in gene expression dynamics during pluripotency and differentiation. Education PhD in Genetics, Stanford University (1995) Research Interests Dr. Hendrich investigates how chromatin structure and epigenetic regulators influence developmental decisions in pluripotent cells. His work bridges stem cell biology, molecular genetics, and chromatin remodeling, aiming to understand mechanisms linking gene regulation to diseases like cancer. Publications Trends His recent studies highlight the NuRD complex’s role in transcriptional noise suppression , lineage commitment , and 3D genome organization during stem cell differentiation, often using advanced techniques like single-cell Hi-C and live-cell imaging. Grants & Collaborations Wellcome Trust Medical Research Council (MRC) Wolfson College AstraZeneca Laboratory & Team Based at the Jeffrey Cheah Biomedical Centre , his group includes researchers India Baker, Jennifer Balmer, Prajakta Gade, Kateryna Kravchenko, Xiaoyan Ma, Seun Ogundele, Ramy Ragheb, and Nicola Reynolds. The lab integrates biochemical, genomic, and imaging approaches to decode stem cell fate determination.

Official University Profile

Catherine WilsonView profile

Associate Professor

University of CambridgeUnited Kingdom

Dr Catherine Wilson is an Associate Professor and Group Leader in the Department of Pharmacology at the University of Cambridge , embedded within the School of Biological Sciences . She also serves as Governing Body Fellow of Wolfson College. Since 2019 she has led an independent research programme investigating how the cancer gene Myc can be harnessed for regenerative medicine. Education PhD, Department of Medical Genetics, Cardiff University – Thesis on Harmatin (Tsc1) in renal cell carcinoma models under Professors Julian Sampson & Jeremy Cheadle Research Interests Dr Wilson’s laboratory focuses on the pleiotropic transcription factor Myc , which is deregulated in most human cancers. By developing acutely switchable genetic models (MycER TM ), her team interrogates the immediate molecular consequences of turning Myc on or off in tissues such as the heart. Key discoveries include the requirement for Cyclin T1 (Ccnt1) to enable Myc-driven transcription and cardiomyocyte proliferation—findings that open dual therapeutic avenues: Oncology: Selective inhibition of Cyclin T1 to suppress Myc-driven tumours. Regenerative Medicine: Reactivation of Myc transcription for cardiac repair after myocardial infarction. The group combines in vivo mouse genetics, single-cell transcriptomics, mass-spectrometry imaging, and high-throughput screening to dissect these mechanisms. Funding & Support Current research is generously supported by: Medical Research Council (MRC) British Heart Foundation (BHF) AstraZeneca (industry partnerships) The Royal Society Cambridge Trust & Wolfson College studentships Laboratory & Team The Wilson Lab comprises 4 post-doctoral researchers, 7 PhD students, 1 research assistant, and 1 animal technician. Collaborations span the UK, Europe and Australia, with active projects in cancer gene validation, lipidomic profiling of tumours, and translational cardiac regeneration studies.

Official University Profile

Bin GuView profile

Assistant Professor

Michigan State UniversityUnited States

Bin Gu is an Assistant Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at Michigan State University's College of Human Medicine. His research focuses on molecular mechanisms of early embryo development and genetic diseases, particularly using genome editing and stem cell technologies. He leads the Gu lab, which develops genetically engineered mouse models to study cancers like NUT Carcinoma caused by fusion genes. Dr. Gu holds a Ph.D. in Cell Biology from Zhejiang University and completed postdoctoral training in Developmental and Stem Cell Biology at Canada's Hospital for Sick Children. His work bridges basic research with translational goals, aiming to uncover therapeutic strategies through in vivo models. Research interests include molecular oncogenesis, epigenetic modifiers, and the application of CRISPR/Cas9 for genetic disease modeling. His lab has pioneered mouse models for NUT carcinoma and MECP2 duplication syndrome, leveraging advanced genome-editing techniques. Recent publications emphasize protein-specific imaging, fusion gene oncogenesis, and developmental signaling pathways critical for pregnancy and embryonic processes. Despite no explicitly listed awards here, his contributions to mouse model development and cancer research indicate significant scholarly impact. Advising and grant information are not detailed in the provided text, though his lab's technical innovations suggest active collaborative research programs. The lab's focus on nanomaterials for imaging and protein degradation tools expands into biomedical engineering applications.

Official University Profile

Ursula H. Winzer-SerhanView profile

Associate Professor

Texas A&M UniversityUnited States

Dr. Ursula H. Winzer-Serhan is an Associate Professor in the Department of Neuroscience & Experimental Therapeutics at Texas A&M University School of Medicine. Her research focuses on gene-environment interactions shaping brain development, particularly the effects of early-life exposure to psychoactive drugs like nicotine and alcohol. Her work addresses long-term cognitive, behavioral, and neurophysiological impacts, with emphasis on nicotinic acetylcholine receptors (nAChRs). Education: PhD in Cell Biology, University of Bremen, Germany (1989) Research Associate, Department of Pharmacology, U.C.-Irvine Research Interests: Mechanisms of nAChR function across lifespan Developmental nicotine exposure consequences 15q13.3 microdeletion syndrome modeling (Df[h15q13/+] mice) Neuro-immune interactions in epilepsy Behavioral pharmacology using optogenetics and fiber-photometry Lab Methodologies: Electrophysiology, calcium/dopamine imaging, genetically modified mouse models, behavioral assays, and collaborative neuro-immunology studies with Dr. Samba Reddy. Labs/Teams: The Serhan Lab at Texas A&M studies nAChR physiology/pathology, developmental neurotoxicology, and translational epilepsy research. Current projects include drug self-administration studies and immune challenge experiments in mouse models.

Official University Profile

Klaus PfefferView profile

Professor

Leibniz Institute for NeurobiologyGermany

Klaus Pfeffer is a Full Professor (W3/C4) and Director of the Institute of Medical Microbiology and Hospital Hygiene at Heinrich Heine University Düsseldorf, where he leads research on antimicrobial immunity. His group focuses on IFN-induced GTPases (mGBPs) and their role in combating intracellular pathogens like Toxoplasma gondii , Listeria , and Chlamydia using molecular biology, confocal microscopy, and genetically modified mouse models. Additional research examines lymphotoxin receptor signaling in immune defense and microbiome analysis via whole-genome sequencing. Education & Career: • Medical degree (1987) and Dr. med. (1988) from University of Ulm • Habilitation in Microbiology/Immunology (1996) at Technical University of Munich • Full professorship at HHU Düsseldorf since 2002 Key Research Areas: • Molecular mechanisms of IFN-induced GTPases in pathogen control • Lymphotoxin β receptor signaling in infection defense • Jak2 kinase in innate immunity • Microbiome dynamics in hematological diseases Major Awards: • Gottfried Wilhelm Leibniz Prize (DFG, 2004) • Erdeniin Ochir Medal (Mongolia, 2018) • Honorary Professorship (Mongolian National University, 2014) Leadership & Projects: • Speaker of Jürgen Manchot Graduate School "Molecules of Infection" • Principal Investigator in DFG Research Units (e.g., RTG 1949, FOR 729) • Current projects include functional analysis of GBPs in chlamydia defense and LTβR-mediated immunity

Official University Profile

Thomas Mark ConlonView profile

Researcher

Helmholtz Centre MunichGermany

Dr. Thomas Mark Conlon serves as Group Leader of the Immunopathology of COPD research team at the Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, Germany. Appointed to this leadership role in 2021 after joining as a Post-Doc in 2013, he directs investigations into immune mechanisms driving chronic lung disease within the Comprehensive Pneumology Center consortium. His educational foundation includes a 2005 PhD from the University of Cambridge's Department of Pathology, where he studied immunoglobulin gene diversification, followed by seven years of postdoctoral research in Cambridge's Department of Surgery examining T/B cell interactions in chronic allograft rejection using heart transplant models. This translational trajectory culminated in his current focus on COPD immunopathogenesis. Conlon's research program spans two interconnected domains: First, elucidating how adaptive immunity modulates tissue injury and regeneration in COPD, highlighted by his landmark Nature demonstration that LTβR blockade resolves tertiary lymphoid organs while reactivating WNT/β-catenin pathways to reverse emphysema. Second, investigating epigenetic drivers like PRMT7-mediated histone methylation in monocyte migration, revealing novel mechanisms of tissue injury in Nature Communications . His work consistently targets therapeutic reactivation of endogenous lung repair systems. Publication trends reveal deepening exploration of immune-metabolic crosstalk (2023 oxysterol/SARS-CoV-2 study) and epigenetic regulation (2022 PRMT7 paper), with consistent focus on translating basic immunological discoveries into regenerative therapies for the world's third-leading cause of death. His contributions have earned significant recognition: 2022 International Travel Scholarship Award from the American Thoracic Society 2018 Prize of Excellence in Lung Research at MLC/DZL symposium 2017 UHU Seed Funding Award from University of Western Australia Securing competitive seed funding and international travel grants, Conlon's work bridges fundamental immunology and clinical translation. His lab maintains active collaborations within the Yildirim/Conlon research ecosystem, focusing on therapeutic targeting of lymphotoxin signaling and epigenetic modifiers. The Conlon Lab operates within Helmholtz Munich's state-of-the-art facilities at the Comprehensive Pneumology Center, leveraging advanced mouse models, epigenetic profiling, and human tissue analysis to dissect immune mechanisms in chronic lung disease. Current efforts prioritize identifying druggable targets for reversing COPD progression through immune modulation.

Official University Profile

Vladimir LjubicicView profile

Associate Professor

McMaster UniversityCanada

Vladimir Ljubicic is an Associate Professor at McMaster University in the Department of Kinesiology , holding the Canada Research Chair (Tier 2) in Neuromuscular Plasticity in Health and Disease . His research focuses on molecular mechanisms of neuromuscular plasticity, particularly identifying therapeutic targets for neuromuscular disorders. Academic background includes a Ph.D. and M.Sc. from York University and postdoctoral training at the University of Ottawa (2009-2014) . He teaches graduate and undergraduate courses in Kinesiology , including Integrative Cell and Molecular Exercise Physiology and Neuromuscular Plasticity in Health and Disease . His research integrates cellular and whole-animal models to study phenotype-modifying proteins like AMPK and CARM1 in neuromuscular junction biology , mitochondrial function , and exercise-induced adaptations . Recent work highlights CARM1 in autophagy regulation and AMPK as mitochondrial medicine for neuromuscular disorders. Scientific awards include the CSEP Young Investigator Award (2022) and CIHR research funding (2021) . His lab, the Integrative Neuromuscular Biology Laboratory , emphasizes equity, diversity, and inclusion in research and mentorship.

Official University Profile

Friedrich Rainer von CoellnView profile

Assistant Professor

University of Maryland, BaltimoreUnited States

Friedrich Rainer von Coelln serves as Assistant Professor in the Department of Neurology at the University of Maryland School of Medicine, specializing in Parkinson's disease and complex movement disorders including atypical parkinsonism (PSP, MSA, CBS/CBD), dystonia, tremor, and gait disorders. His clinical practice integrates advanced diagnostic approaches for both primary Parkinsonian syndromes and 'PD-look-alikes,' with particular expertise in quantitative motor assessment. Education: Medical School: Ruprecht-Karls University, Heidelberg, Germany Internship: Harbor Hospital, Baltimore, Maryland Neurology Residency: University Hospital Tübingen, Germany & University of Maryland Medical System Fellowship: Johns Hopkins University, Department of Neurology (Movement Disorders) Certifications: American Board of Psychiatry and Neurology; Board-certified Neurologist, Germany Dr. von Coelln's research program centers on genotype-phenotype correlations in Parkinson's disease, pioneering the implementation of wearable biosensors for objective gait and balance analysis. His 'next-generation phenotyping' approach bridges clinical neurology with digital biomarker development, focusing on how genetic variability influences motor symptom expression. This work has evolved from foundational molecular studies on parkin pathways to current sensor-based clinical validation, reflecting a career-long commitment to translating basic mechanisms into improved patient assessment tools. His publication history reveals consistent focus on Parkinson's disease mechanisms and clinical phenotyping, with recent work emphasizing wearable sensor validation and genetic heterogeneity analysis. The trajectory shows progression from animal model studies (1995-2007) to contemporary clinical sensor applications (2015-2016), maintaining core interest in neurodegenerative mechanisms while adopting innovative measurement technologies. Scientific Awards: 2-year career development grant by American Academy of Neurology & American Brain Foundation (2014) Pilot grant from University of Maryland Claude D. Pepper Older Americans Independence Center (UM-OAIC) Dr. von Coelln has secured competitive grant funding supporting his dual focus on genetic correlations and sensor-based phenotyping in Parkinson's disease. His collaborative research network includes prominent neurodegeneration researchers from Johns Hopkins and German institutions, reflecting transatlantic scientific engagement. While student mentorship details aren't specified in source materials, his faculty role involves training neurology residents and fellows in movement disorders management. Current work centers on validating portable biosensors for clinical use while exploring genetic modifiers of motor symptoms, positioning his lab at the intersection of digital health and neurogenetics. Based at the University of Maryland's Paca/Pratt clinical facility, he maintains an active translational research program alongside clinical practice, with recent efforts focused on implementing 'deep phenotyping' approaches for precision neurology in movement disorders.

Official University Profile

Nadia RosenthalView profile

Professor

Human TechnopoleItaly

Nadia Rosenthal serves as Scientific Director of The Jackson Laboratory in Bar Harbor, Maine, and holds a Professorial Chair in Cardiovascular Sciences at Imperial College London. Her career includes directing a biomedical research laboratory at Harvard Medical School, heading the European Molecular Biology Laboratory (EMBL) campus in Rome, founding EMBL Australia as Chief Scientist, and establishing the Australian Regenerative Medicine Institute in Melbourne as its founding director. She earned her PhD from Harvard Medical School, forming the foundation of her research trajectory in molecular biology and regenerative medicine. Her academic journey spans multiple international institutions with leadership roles in major research organizations. Professor Rosenthal's research centers on regenerative medicine mechanisms, specifically investigating how growth factors, stromal cells, and immune system interactions resolve tissue damage. Her team pioneered methods to modify immune cell infiltration profiles to control tissue repair processes and leveraged mouse genetic diversity to uncover novel pathways in cardiovascular disease response variability. Since 2019, they have developed precision mouse models for SARS-CoV-2 research, demonstrating cross-disciplinary applications of mouse genetics in infectious disease modeling. Her scientific recognition includes: EMBO Fellowship Fellowship in the UK Academy of Medical Sciences Fellowship in the Australian Academy of Health and Medical Sciences She leads a research team at The Jackson Laboratory focused on translating fundamental discoveries in tissue regeneration into clinical applications, with particular emphasis on cardiovascular pathologies and immune modulation strategies. Her work bridges basic science and translational medicine through innovative genetic approaches.

Official University Profile

Yizhou HuView profile

Researcher

Karolinska InstitutetSweden

Yizhou Hu is a Principal Researcher at the Department of Laboratory Medicine, Karolinska Institutet, Sweden, and holds a concurrent position as University Researcher at the Faculty of Medicine, University of Helsinki & Wihuri Institute, Finland. With extensive expertise in single-cell analysis and computational biology, Hu leads cutting-edge research at the intersection of cancer biology, neuroscience, and dermatology. Dr. Hu's educational background includes a Ph.D. in Pathology (Oncology and Molecular Cell Biology) from the University of Helsinki (2017) and an M.Sc. in Genetics from the same institution (2011). Additional training includes postdoctoral research at Karolinska Institutet's Division of Molecular Neurobiology (2017-2022) supported by an SSMF fellowship. Research interests center on two major themes: Developmental Plasticity in Nervous System Cancers focusing on glioblastoma and neuroblastoma mechanisms, and Immune Priming of Non-Immune Cells in Psoriatic Skin . Hu employs advanced methodologies including single-cell MultiOmics, spatial transcriptomics, deep-learning analytics (scCAMEL), human organoids, and genetically modified animal models to investigate cellular heterogeneity and disease mechanisms. The publication record demonstrates consistent high-impact contributions across cancer biology, neuroscience, and dermatology. Recent work (2023-2025) shows increasing integration of machine learning with multi-omics approaches, particularly in neuroblastoma developmental plasticity, pain pathway characterization, and psoriasis inflammation mechanisms. The research spans basic science to translational applications with strong emphasis on cellular heterogeneity. Scientific recognition includes: SSMF fellowship (2020-2022) Dr. Hu has developed innovative computational tools including the scCAMEL suite (scCAMEL-SWAPLINE, scCAMEL-VICUNA, scCAMEL-EVO) for single-cell analysis, with publicly available datasets and visualization platforms for psoriasis research. Current work focuses on identifying cellular and molecular mechanisms driving high-risk neuroblastoma and glioblastoma, with emphasis on developmental trajectories that could inform targeted therapeutic approaches. The research program maintains strong collaborative networks across Karolinska Institutet, University of Helsinki, and international institutions, with particular emphasis on neural crest-derived cancer lineages and skin immunology mechanisms.

Official University Profile

Elizabeth M McNallyView profile

Professor

Northwestern UniversityUnited States

Elizabeth M McNally is the Director of the Center for Genetic Medicine and the Elizabeth J. Ward Professor of Genetic Medicine at the Feinberg School of Medicine, Northwestern University . She serves as a Professor in the Departments of Medicine (Cardiology) and Biochemistry and Molecular Genetics. Education: MD and PhD from Albert Einstein College of Medicine (1990) Residency in Internal Medicine at Brigham & Women's Hospital Fellowships in Cardiovascular Medicine and Genetics Research Interests: McNally investigates the genetic mechanisms underlying inherited cardiovascular and neuromuscular disorders , including heart failure, cardiomyopathy, muscular dystrophy, and arrhythmias. Her work focuses on gene editing, membrane repair, and disease modeling using induced pluripotent stem cells and computational genomics. Publications & Research Trends: Her recent studies explore gene-gene interactions, inflammation in muscle diseases, and therapeutic strategies such as antisense exon skipping, LTBP4 modulation, and polygenic risk score implementation. These span genetic medicine, cardiovascular biology, and translational therapeutics . Scientific Awards: Walder Award (2023) National Academy of Medicine member (2021) American Academy of Arts and Sciences (2021) American Heart Association Medal of Honor (2020) Doris Duke Distinguished Clinical Scientist Award (2007) Leadership & Service: She serves as Editor-in-Chief of the Journal of Clinical Investigation , President of the Association of American Physicians, and on scientific advisory boards for Muscular Dystrophy Association and Tenaya Therapeutics. Her team advances genomic therapies for muscle and heart disorders.

Official University Profile